Income from Continuous Operations: A company's total income or loss before discontinued operations, extraordinary items, preferred stock dividends and accounting change.
Edgewise Therapeutics, Inc. (EWTX) had Income from Continuous Operations of $-50.22M for the most recently reported fiscal quarter, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-50.22M |
|
-- |
|
-- |
|
$55.98M |
|
$-55.98M |
|
$5.76M |
|
$-50.22M |
|
$-50.22M |
|
$-50.22M |
|
|
Income from Continuous Operations |
$-50.22M |
$-50.22M |
|
$-50.22M |
|
$-55.98M |
|
$-56.89M |
|
102.93M |
|
102.93M |
|
$-0.47 |
|
$-0.47 |
|
| Balance Sheet Financials | |
$543.38M |
|
$7.83M |
|
$9.22M |
|
$552.60M |
|
$27.37M |
|
-- |
|
$2.98M |
|
$30.35M |
|
$522.26M |
|
$522.26M |
|
$522.26M |
|
106.25M |
|
| Cash Flow Statement Financials | |
$-143.82M |
|
$-32.79M |
|
$196.09M |
|
$41.67M |
|
$61.15M |
|
$19.48M |
|
$34.75M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
19.85 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-144.07M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-9.62% |
|
-9.62% |
|
-9.09% |
|
-9.62% |
|
$4.92 |
|
$-1.40 |
|
$-1.40 |
|